JP2021045174A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021045174A5 JP2021045174A5 JP2020219029A JP2020219029A JP2021045174A5 JP 2021045174 A5 JP2021045174 A5 JP 2021045174A5 JP 2020219029 A JP2020219029 A JP 2020219029A JP 2020219029 A JP2020219029 A JP 2020219029A JP 2021045174 A5 JP2021045174 A5 JP 2021045174A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid insert
- ltvec
- sequence
- homology arm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 76
- 108020004707 nucleic acids Proteins 0.000 claims 72
- 102000039446 nucleic acids Human genes 0.000 claims 72
- 238000000034 method Methods 0.000 claims 22
- 101710163270 Nuclease Proteins 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 230000037430 deletion Effects 0.000 claims 8
- 238000012217 deletion Methods 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 108020005004 Guide RNA Proteins 0.000 claims 5
- 230000010354 integration Effects 0.000 claims 5
- 108020004414 DNA Proteins 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108091033409 CRISPR Proteins 0.000 claims 3
- 241000894007 species Species 0.000 claims 3
- 108700028369 Alleles Proteins 0.000 claims 2
- 238000010354 CRISPR gene editing Methods 0.000 claims 2
- 108700008625 Reporter Genes Proteins 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 210000001161 mammalian embryo Anatomy 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 230000002103 transcriptional effect Effects 0.000 claims 2
- 238000010459 TALEN Methods 0.000 claims 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462094104P | 2014-12-19 | 2014-12-19 | |
| US62/094,104 | 2014-12-19 | ||
| US201562167408P | 2015-05-28 | 2015-05-28 | |
| US62/167,408 | 2015-05-28 | ||
| US201562205524P | 2015-08-14 | 2015-08-14 | |
| US62/205,524 | 2015-08-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532808A Division JP6840077B2 (ja) | 2014-12-19 | 2015-12-18 | 単一ステップの複数標的化を通じた標的化された遺伝子修飾のための方法及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021045174A JP2021045174A (ja) | 2021-03-25 |
| JP2021045174A5 true JP2021045174A5 (cg-RX-API-DMAC7.html) | 2021-05-06 |
| JP7095066B2 JP7095066B2 (ja) | 2022-07-04 |
Family
ID=55229831
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532808A Active JP6840077B2 (ja) | 2014-12-19 | 2015-12-18 | 単一ステップの複数標的化を通じた標的化された遺伝子修飾のための方法及び組成物 |
| JP2020219029A Active JP7095066B2 (ja) | 2014-12-19 | 2020-12-28 | 単一ステップの複数標的化を通じた標的化された遺伝子修飾のための方法及び組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532808A Active JP6840077B2 (ja) | 2014-12-19 | 2015-12-18 | 単一ステップの複数標的化を通じた標的化された遺伝子修飾のための方法及び組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11326184B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3653048B9 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6840077B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102530821B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107208113A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015364427B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017013104A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2971213C (cg-RX-API-DMAC7.html) |
| ES (2) | ES2760508T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL252755B (cg-RX-API-DMAC7.html) |
| MX (1) | MX388784B (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ732895A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2707137C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201704646YA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016100819A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2847335T (pt) | 2012-04-25 | 2018-09-28 | Regeneron Pharma | Alvejamento mediado por nuclease com vetores de alvejamento grandes |
| HUE040575T2 (hu) | 2013-04-16 | 2019-03-28 | Regeneron Pharma | A patkány genom célzott módosítása |
| US9546384B2 (en) | 2013-12-11 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a mouse genome |
| LT3152312T (lt) | 2014-06-06 | 2020-04-27 | Regeneron Pharmaceuticals, Inc. | Tikslinio lokuso modifikavimo būdai ir kompozicijos |
| EP3461885B1 (en) | 2014-06-26 | 2021-10-20 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modifications and methods of use |
| EP3204496A1 (en) | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| JP2017536811A (ja) | 2014-10-15 | 2017-12-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 多能性細胞の樹立又は維持のための方法及び組成物 |
| WO2016073990A2 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
| HUE044907T2 (hu) | 2014-11-21 | 2019-11-28 | Regeneron Pharma | Módszerek és készítmények célzott genetikai módosításhoz, párosított mutató RNS-ek használatával |
| NZ732895A (en) | 2014-12-19 | 2022-05-27 | Regeneron Pharma | Methods and compositions for targeted genetic modification through single-step multiple targeting |
| ES3009538T3 (en) | 2015-05-29 | 2025-03-27 | Regeneron Pharma | Rodent cells having a disruption in a c9orf72 locus |
| CA2999500A1 (en) | 2015-09-24 | 2017-03-30 | Editas Medicine, Inc. | Use of exonucleases to improve crispr/cas-mediated genome editing |
| KR102482103B1 (ko) | 2016-01-13 | 2022-12-28 | 리제너론 파마슈티칼스 인코포레이티드 | 조작된 중쇄 다양성 영역을 갖는 설치류 |
| EP3433363A1 (en) | 2016-03-25 | 2019-01-30 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
| WO2017180694A1 (en) | 2016-04-13 | 2017-10-19 | Editas Medicine, Inc. | Cas9 fusion molecules gene editing systems, and methods of use thereof |
| KR102294755B1 (ko) | 2016-09-30 | 2021-08-31 | 리제너론 파마슈티칼스 인코포레이티드 | C9orf72 유전자좌에서 헥사뉴클레오티드 반복 확장을 갖는 비인간 동물 |
| PL3766343T3 (pl) | 2016-11-04 | 2022-09-26 | Regeneron Pharmaceuticals, Inc. | Zwierzęta inne niż człowiek posiadające zmodyfikowany sposobami inżynierii locus łańcucha lekkiego lambda immunoglobuliny |
| US20190359973A1 (en) * | 2017-01-10 | 2019-11-28 | Christiana Care Health Services, Inc. | Methods for in vitro site-directed mutagenesis using gene editing technologies |
| US11866726B2 (en) | 2017-07-14 | 2024-01-09 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| US11021719B2 (en) * | 2017-07-31 | 2021-06-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for assessing CRISPER/Cas-mediated disruption or excision and CRISPR/Cas-induced recombination with an exogenous donor nucleic acid in vivo |
| PT3720279T (pt) | 2017-12-05 | 2022-10-06 | Regeneron Pharma | Ratinhos tendo uma cadeia leve lambda de imunoglobulina manipulada e seus usos |
| IL318469A (en) | 2018-06-14 | 2025-03-01 | Regeneron Pharma | Non-human animals capable of reorganizing transgenic DH-DH, and their uses |
| CN111321171A (zh) * | 2018-12-14 | 2020-06-23 | 江苏集萃药康生物科技有限公司 | 一种应用CRISPR/Cas9介导ES打靶技术制备基因打靶动物模型的方法 |
| CN113423831B (zh) | 2018-12-20 | 2023-03-10 | 瑞泽恩制药公司 | 核酸酶介导的重复扩增 |
| CN113795588B (zh) * | 2019-04-04 | 2025-02-25 | 瑞泽恩制药公司 | 用于在靶向性载体中无瘢痕引入靶向修饰的方法 |
| CA3136478A1 (en) | 2019-06-05 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof |
| EP4559939A3 (en) | 2020-12-23 | 2025-09-24 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses therof |
| US20250027116A1 (en) * | 2021-09-24 | 2025-01-23 | Immunocan Biotech Co. Ltd. | Methods for large-size chromosomal transfer and modified chromosomes and organisims using same |
| WO2024091578A2 (en) * | 2022-10-27 | 2024-05-02 | Seawolf Therapeutics, Inc. | Nuclear targeted dna delivery and compositions for use in practicing the same |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU664976B2 (en) * | 1990-08-29 | 1995-12-14 | Gene Pharming Europe Bv | Homologous recombination in mammalian cells |
| US5830729A (en) | 1996-04-18 | 1998-11-03 | Institut Pasteur | I Sce I-induced gene replacement and gene conversion in embryonic stem cells |
| AU8587598A (en) | 1997-07-26 | 1999-02-16 | Wisconsin Alumni Research Foundation | Trans-species nuclear transfer |
| WO2000039316A1 (en) | 1998-12-31 | 2000-07-06 | The J. David Gladstone Institutes | Transgenic rodents and rodent cell lines expressing hiv co-receptors |
| US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
| US6503717B2 (en) | 1999-12-06 | 2003-01-07 | Sangamo Biosciences, Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
| US20030104526A1 (en) | 1999-03-24 | 2003-06-05 | Qiang Liu | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) * | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2002046412A2 (en) | 2000-12-07 | 2002-06-13 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
| ES2409080T3 (es) | 2001-01-22 | 2013-06-24 | Sangamo Biosciences Inc. | Proteínas de unión con dedos de zinc modificadas |
| WO2002057308A2 (en) | 2001-01-22 | 2002-07-25 | Sangamo Biosciences, Inc. | Zinc finger polypeptides and their use |
| AUPR451401A0 (en) | 2001-04-20 | 2001-05-24 | Monash University | A method of nuclear transfer |
| CN100575485C (zh) | 2002-01-23 | 2009-12-30 | 犹他大学研究基金会 | 使用锌指核酸酶的定向染色体诱变 |
| EP1485475B2 (en) | 2002-03-15 | 2017-09-20 | Cellectis | Hybrid and single chain meganucleases and use thereof |
| EP2368982A3 (en) | 2002-03-21 | 2011-10-12 | Sangamo BioSciences, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| US7612250B2 (en) | 2002-07-29 | 2009-11-03 | Trustees Of Tufts College | Nuclear transfer embryo formation method |
| JP2006502748A (ja) | 2002-09-05 | 2006-01-26 | カリフォルニア インスティテュート オブ テクノロジー | 遺伝子ターゲッティングを誘発するキメラヌクレアーゼの使用方法 |
| WO2004031346A2 (en) | 2002-09-06 | 2004-04-15 | Fred Hutchinson Cancer Research Center | Methods and compositions concerning designed highly-specific nucleic acid binding proteins |
| US20030175968A1 (en) | 2002-10-30 | 2003-09-18 | Golic Kent G. | Gene targeting method |
| WO2004063356A2 (en) | 2003-01-13 | 2004-07-29 | Rao Mahendra S | Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| EP1591521A1 (en) | 2004-04-30 | 2005-11-02 | Cellectis | I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof |
| EP1789095A2 (en) | 2004-09-16 | 2007-05-30 | Sangamo Biosciences Inc. | Compositions and methods for protein production |
| PL1802193T3 (pl) | 2004-10-19 | 2014-09-30 | Regeneron Pharma | Sposób wytwarzania myszy homozygotycznej pod względem modyfikacji genetycznej |
| FR2879622B1 (fr) | 2004-12-17 | 2008-02-01 | Agronomique Inst Nat Rech | Procede in vitro de production d'ovocytes ou d'oeufs presentant une modification genomique ciblee |
| WO2006097784A1 (en) | 2005-03-15 | 2006-09-21 | Cellectis | I-crei meganuclease variants with modified specificity, method of preparation and uses thereof |
| WO2006097854A1 (en) | 2005-03-15 | 2006-09-21 | Cellectis | Heterodimeric meganucleases and use thereof |
| GB0615327D0 (en) | 2006-03-30 | 2006-09-13 | Univ Edinburgh | Culture medium containing kinase inhibitors and uses thereof |
| EP2003960B1 (en) | 2006-03-31 | 2015-06-10 | E. R. Squibb & Sons, L.L.C. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| CN101117633B (zh) | 2006-08-03 | 2011-07-20 | 上海交通大学附属儿童医院 | 一种细胞核移植方法 |
| PT2415873E (pt) | 2006-12-14 | 2015-03-31 | Sangamo Biosciences Inc | Proteínas com dedos de zinco não canónicas optimizadas |
| US7771967B2 (en) | 2006-12-22 | 2010-08-10 | The J. David Gladstone Institutes | Nucleic acid encoding apolipoprotein E-I3 |
| EP2137310B1 (en) | 2007-04-26 | 2010-11-24 | Sangamo BioSciences, Inc. | Targeted integration into the ppp1r12c locus |
| SI2602323T1 (en) | 2007-06-01 | 2018-05-31 | Open Monoclonal Technology, Inc. | Compositions and procedures for inhibiting endogenous immunoglobin gene and the formation of transgenic human idiopathic antibodies |
| GB0803109D0 (en) * | 2008-02-20 | 2008-03-26 | Gene Bridges Gmbh | Method of nucleic acid recombination |
| CA2745031C (en) | 2008-12-04 | 2018-08-14 | Sangamo Biosciences, Inc. | Genome editing in rats using zinc-finger nucleases |
| EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
| US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
| CA2755192C (en) | 2009-03-20 | 2018-09-11 | Sangamo Biosciences, Inc. | Modification of cxcr4 using engineered zinc finger proteins |
| US8772008B2 (en) | 2009-05-18 | 2014-07-08 | Sangamo Biosciences, Inc. | Methods and compositions for increasing nuclease activity |
| US20120178647A1 (en) | 2009-08-03 | 2012-07-12 | The General Hospital Corporation | Engineering of zinc finger arrays by context-dependent assembly |
| US20120276537A1 (en) | 2009-10-28 | 2012-11-01 | Kuehn Ralf | Homologous recombination in the oocyte |
| JP5908405B2 (ja) | 2009-10-29 | 2016-04-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 多機能性対立遺伝子 |
| US20120315670A1 (en) | 2009-11-02 | 2012-12-13 | Gen9, Inc. | Compositions and Methods for the Regulation of Multiple Genes of Interest in a Cell |
| EP2508595B1 (en) | 2009-12-01 | 2016-11-23 | National Cancer Center | Method for constructing chimeric rat using rat embryonic stem cells |
| HUE041436T2 (hu) | 2009-12-10 | 2019-05-28 | Univ Minnesota | Tal-effektor-közvetített DNS-módosítás |
| AU2010335107B2 (en) | 2009-12-21 | 2014-07-03 | Keygene N.V. | Improved techniques for transfecting protoplasts |
| JP2013518602A (ja) | 2010-02-09 | 2013-05-23 | サンガモ バイオサイエンシーズ， インコーポレイテッド | 部分的に一本鎖のドナー分子による標的化ゲノム改変 |
| GB201009732D0 (en) | 2010-06-10 | 2010-07-21 | Gene Bridges Gmbh | Direct cloning |
| CN102933074B (zh) | 2010-06-11 | 2015-04-08 | 瑞泽恩制药公司 | 由xy es细胞制备能育的xy雌性动物 |
| CA2805442C (en) | 2010-07-21 | 2020-05-12 | Sangamo Biosciences, Inc. | Methods and compositions for modification of an hla locus |
| SG187075A1 (en) | 2010-07-23 | 2013-03-28 | Sigma Aldrich Co Llc | Genome editing using targeting endonucleases and single-stranded nucleic acids |
| WO2012018726A1 (en) | 2010-08-02 | 2012-02-09 | Cellectis Sa | Method for increasing double-strand break-induced gene targeting |
| WO2012129198A1 (en) | 2011-03-23 | 2012-09-27 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for obesity and diabetes |
| IN2014CN03890A (cg-RX-API-DMAC7.html) | 2011-10-28 | 2015-10-16 | Regeneron Pharma | |
| WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| PT2847335T (pt) | 2012-04-25 | 2018-09-28 | Regeneron Pharma | Alvejamento mediado por nuclease com vetores de alvejamento grandes |
| AU2013259647B2 (en) | 2012-05-07 | 2018-11-08 | Corteva Agriscience Llc | Methods and compositions for nuclease-mediated targeted integration of transgenes |
| WO2013176772A1 (en) | 2012-05-25 | 2013-11-28 | The Regents Of The University Of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| CN110643600A (zh) | 2012-10-23 | 2020-01-03 | 基因工具股份有限公司 | 用于切割靶dna的系统及其用途 |
| LT3138910T (lt) | 2012-12-06 | 2017-11-10 | Sigma-Aldrich Co. Llc | Crispr pagrįstas genomo modifikavimas ir reguliavimas |
| SG10201707569YA (en) | 2012-12-12 | 2017-10-30 | Broad Inst Inc | Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| ES2786193T3 (es) | 2012-12-12 | 2020-10-09 | Broad Inst Inc | Modificación por tecnología genética y optimización de sistemas, métodos y composiciones enzimáticas mejorados para la manipulación de secuencias |
| ES2963516T3 (es) * | 2012-12-14 | 2024-03-27 | Omniab Inc | Polinucleótidos que codifican anticuerpos de roedores con idiotipos humanos y animales que los contienen |
| SG10201704932UA (en) | 2012-12-17 | 2017-07-28 | Harvard College | Rna-guided human genome engineering |
| CN105025701B (zh) | 2012-12-27 | 2018-09-25 | 凯津公司 | 去除植物中遗传连锁的方法 |
| EP3561050B1 (en) | 2013-02-20 | 2021-12-08 | Regeneron Pharmaceuticals, Inc. | Genetic modification of rats |
| WO2014131833A1 (en) | 2013-02-27 | 2014-09-04 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Gene editing in the oocyte by cas9 nucleases |
| WO2014143381A1 (en) | 2013-03-09 | 2014-09-18 | Agilent Technologies, Inc. | Methods of in vivo engineering of large sequences using multiple crispr/cas selections of recombineering events |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| EP2975942B1 (en) | 2013-03-21 | 2018-08-08 | Sangamo Therapeutics, Inc. | Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases |
| HUE040575T2 (hu) | 2013-04-16 | 2019-03-28 | Regeneron Pharma | A patkány genom célzott módosítása |
| DE202014010413U1 (de) | 2013-09-18 | 2015-12-08 | Kymab Limited | Zellen und Organismen |
| US10787684B2 (en) | 2013-11-19 | 2020-09-29 | President And Fellows Of Harvard College | Large gene excision and insertion |
| US9546384B2 (en) | 2013-12-11 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a mouse genome |
| MX2016007797A (es) | 2013-12-19 | 2016-09-07 | Amyris Inc | Metodos para integracion genomica. |
| WO2015163733A1 (en) | 2014-04-24 | 2015-10-29 | Institute For Basic Science | A method of selecting a nuclease target sequence for gene knockout based on microhomology |
| GB201407852D0 (en) | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
| LT3152312T (lt) | 2014-06-06 | 2020-04-27 | Regeneron Pharmaceuticals, Inc. | Tikslinio lokuso modifikavimo būdai ir kompozicijos |
| EP3461885B1 (en) | 2014-06-26 | 2021-10-20 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modifications and methods of use |
| JP2017529841A (ja) * | 2014-09-19 | 2017-10-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | キメラ抗原受容体 |
| WO2016061073A1 (en) | 2014-10-14 | 2016-04-21 | Memorial Sloan-Kettering Cancer Center | Composition and method for in vivo engineering of chromosomal rearrangements |
| JP2017536811A (ja) | 2014-10-15 | 2017-12-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 多能性細胞の樹立又は維持のための方法及び組成物 |
| JP6772067B2 (ja) | 2014-11-20 | 2020-10-21 | 国立大学法人京都大学 | 哺乳動物の標的ゲノム領域にｄｎａをノックインする方法及び細胞 |
| HUE044907T2 (hu) | 2014-11-21 | 2019-11-28 | Regeneron Pharma | Módszerek és készítmények célzott genetikai módosításhoz, párosított mutató RNS-ek használatával |
| WO2016089866A1 (en) | 2014-12-01 | 2016-06-09 | President And Fellows Of Harvard College | Rna-guided systems for in vivo gene editing |
| NZ732895A (en) | 2014-12-19 | 2022-05-27 | Regeneron Pharma | Methods and compositions for targeted genetic modification through single-step multiple targeting |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
-
2015
- 2015-12-18 NZ NZ732895A patent/NZ732895A/en unknown
- 2015-12-18 RU RU2017124909A patent/RU2707137C2/ru active
- 2015-12-18 EP EP19201384.5A patent/EP3653048B9/en active Active
- 2015-12-18 AU AU2015364427A patent/AU2015364427B2/en active Active
- 2015-12-18 MX MX2017008190A patent/MX388784B/es unknown
- 2015-12-18 JP JP2017532808A patent/JP6840077B2/ja active Active
- 2015-12-18 EP EP15828604.7A patent/EP3232774B1/en active Active
- 2015-12-18 KR KR1020177019826A patent/KR102530821B1/ko active Active
- 2015-12-18 CN CN201580069507.5A patent/CN107208113A/zh active Pending
- 2015-12-18 US US14/974,623 patent/US11326184B2/en active Active
- 2015-12-18 ES ES15828604T patent/ES2760508T3/es active Active
- 2015-12-18 BR BR112017013104A patent/BR112017013104A2/pt not_active Application Discontinuation
- 2015-12-18 CA CA2971213A patent/CA2971213C/en active Active
- 2015-12-18 ES ES19201384T patent/ES2947714T3/es active Active
- 2015-12-18 SG SG11201704646YA patent/SG11201704646YA/en unknown
- 2015-12-18 WO PCT/US2015/066681 patent/WO2016100819A1/en not_active Ceased
-
2017
- 2017-06-07 IL IL252755A patent/IL252755B/en unknown
-
2020
- 2020-12-28 JP JP2020219029A patent/JP7095066B2/ja active Active
-
2022
- 2022-04-05 US US17/713,696 patent/US20220235381A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021045174A5 (cg-RX-API-DMAC7.html) | ||
| JP2017538428A5 (cg-RX-API-DMAC7.html) | ||
| RU2017124909A (ru) | Способы и композиции для нацеленной генетической модификации посредством одноэтапного множественного нацеливания | |
| ES2929110T3 (es) | Composiciones y métodos para mejorar la especificidad en ingeniería genética usando endonucleasas guiadas por ARN | |
| Lo et al. | Precise and heritable genome editing in evolutionarily diverse nematodes using TALENs and CRISPR/Cas9 to engineer insertions and deletions | |
| JP6279562B2 (ja) | 条件付きノックアウト対立遺伝子を生成するための方法および組成物 | |
| Riordan et al. | Application of CRISPR/Cas9 for biomedical discoveries | |
| JP2015514439A5 (cg-RX-API-DMAC7.html) | ||
| CN104805078A (zh) | 用于高效基因组编辑的rna分子的设计、合成及其应用 | |
| JP2017535271A5 (cg-RX-API-DMAC7.html) | ||
| RU2019143133A (ru) | Способы и композиции для нацеленных генетических модификаций и способы их применения | |
| West et al. | Transcriptome analysis of targeted mouse mutations reveals the topography of local changes in gene expression | |
| BR102014027436B1 (pt) | Molécula de ácido nucleico recombinante, e método para a produção de uma célula vegetal transgênica | |
| Kapusi et al. | phiC31 integrase-mediated site-specific recombination in barley | |
| Rezaei et al. | Harnessing CRISPR/Cas9 technology in cardiovascular disease | |
| Yuan et al. | A transgenic core facility’s experience in genome editing revolution | |
| Zhang et al. | Crispr/Cas9‐mediated cleavages facilitate homologous recombination during genetic engineering of a large chromosomal region | |
| Quoseena et al. | Functional role of annexins in zebrafish caudal fin regeneration–A gene knockdown approach in regenerating tissue | |
| US12305168B2 (en) | Materials and methods for efficient targeted knock in or gene replacement | |
| Kondo | New horizons in genome engineering of Drosophila melanogaster | |
| CN105315352B (zh) | 昆虫定点基因敲入组合物及其使用方法和应用 | |
| Li et al. | The present and future of genome editing in cancer research | |
| Liu et al. | Efficient genome editing of genes involved in neural crest development using the CRISPR/Cas9 system in Xenopus embryos | |
| Sakane et al. | A simple protocol for loss-of-function analysis in Xenopus tropicalis founders using the CRISPR-cas system | |
| Musunuru | Genome editing: a practical guide to research and clinical applications |